Cargando…
Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60
SIMPLE SUMMARY: Diffuse large B cell Lymphoma (DLBCL) can be categorized into cell of origin (COO) subtypes. Genetic tests are used to detect which subtype of DLBCL a patient has. One subtype of DLBCL, activated B-cell like (ABC), is associated with a comparatively poorer prognosis. New evidence sug...
Autores principales: | Regier, Dean A., Chan, Brandon, Costa, Sarah, Scott, David W., Steidl, Christian, Connors, Joseph M., Karsan, Aly, Marra, Marco A., Kridel, Robert, Cromwell, Ian, Pollard, Samantha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870002/ https://www.ncbi.nlm.nih.gov/pubmed/35205656 http://dx.doi.org/10.3390/cancers14040908 |
Ejemplares similares
-
Relapse timing is associated with distinct evolutionary dynamics in DLBCL
por: Hilton, Laura K., et al.
Publicado: (2023) -
The cost and cost trajectory of whole‐genome analysis guiding treatment of patients with advanced cancers
por: Weymann, Deirdre, et al.
Publicado: (2017) -
Clinical and cost outcomes following genomics‐informed treatment for advanced cancers
por: Weymann, Deirdre, et al.
Publicado: (2021) -
Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Zhang, Wenqi, et al.
Publicado: (2021) -
Diffuse Large B-Cell Lymphoma (DLBCL) in an Aged Raccoon (Procyon lotor)
por: D’Annunzio, Giulia, et al.
Publicado: (2022)